CAMP4 Therapeutics (CAMP) Stock Forecast, Price Target & Predictions
CAMP Stock Forecast
CAMP4 Therapeutics (CAMP) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $12.50, with a high of $18.00 and a low of $5.00. This represents a 691.14% increase from the last price of $1.58.
CAMP Stock Rating
CAMP4 Therapeutics stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (63.64%), 6 Hold (27.27%), 2 Sell (9.09%), and 0 Strong Sell (0.00%).
Buy
CAMP Price Target Upside V Benchmarks
Type | Name | Upside |
---|---|---|
Stock | CAMP4 Therapeutics | 691.14% |
Sector | Healthcare Stocks | 23.68% |
Industry | Biotech Stocks | 64.77% |
Price Target Trends
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $17.50 |
Last Closing Price | $1.58 | $1.58 | $1.58 |
Upside/Downside | - | - | 1007.59% |
Ratings Trends
Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
---|---|---|---|---|---|---|
Jun, 25 | 2 | 3 | - | - | - | 5 |
May, 25 | 2 | 2 | - | - | - | 4 |
Apr, 25 | 2 | 2 | - | - | - | 4 |
Mar, 25 | 2 | 2 | - | - | - | 4 |
Feb, 25 | 2 | 2 | - | - | - | 4 |
Analyst Price Target Forecasts
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 05, 2024 | Mani Foroohar | Leerink Partners | $17.00 | $9.60 | 77.08% | 975.95% |
Nov 05, 2024 | Edward Tenthoff | Piper Sandler | $18.00 | $9.60 | 87.50% | 1039.24% |
Aug 16, 2022 | Anthony Stoss | Craig-Hallum | $10.00 | $5.80 | 72.41% | 532.91% |
Jun 24, 2022 | Jerry Revich | Goldman Sachs | $5.00 | $4.93 | 1.42% | 216.46% |
Analyst Rating Forecasts
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
May 27, 2025 | Wedbush | Outperform | initialise | |
Nov 05, 2024 | William Blair | Outperform | initialise | |
Nov 05, 2024 | Leerink Partners | Outperform | initialise | |
Nov 05, 2024 | Piper Sandler | Overweight | initialise | |
Jun 26, 2023 | Raymond James | Buy | upgrade | |
Oct 14, 2022 | Goldman Sachs | Sell | Sell | hold |
Jun 24, 2022 | Goldman Sachs | Sell | Sell | hold |
Financial Forecast
EPS Forecast
Annual
Nov 20 | Nov 21 | Nov 22 | Nov 23 | Nov 24 | Nov 25 | Nov 26 | Nov 27 | |
---|---|---|---|---|---|---|---|---|
Reported | - | - | - | $-2.52 | - | - | - | - |
Avg Forecast | $2.86 | $0.77 | $-2.39 | $-5.27 | $-2.10 | $0.95 | $-2.42 | - |
High Forecast | $2.90 | $0.78 | $-2.39 | $-5.27 | $-1.29 | $1.01 | $-2.38 | - |
Low Forecast | $2.81 | $0.75 | $-2.39 | $-5.27 | $-3.23 | $0.86 | $-2.46 | - |
Surprise % | - | - | - | -52.18% | - | - | - | - |
Revenue Forecast
Annual
Nov 20 | Nov 21 | Nov 22 | Nov 23 | Nov 24 | Nov 25 | Nov 26 | Nov 27 | |
---|---|---|---|---|---|---|---|---|
Reported | - | - | - | $186.23M | - | - | - | - |
Avg Forecast | $335.33M | $295.88M | $295.08M | $237.48M | $229.10M | $252.01M | $291.96M | $152.47M |
High Forecast | $338.65M | $298.80M | $295.08M | $237.48M | $241.38M | $264.74M | $291.96M | $152.47M |
Low Forecast | $330.91M | $291.97M | $295.08M | $237.48M | $216.83M | $239.28M | $291.96M | $152.47M |
Surprise % | - | - | - | -21.58% | - | - | - | - |
Net Income Forecast
Annual
Nov 20 | Nov 21 | Nov 22 | Nov 23 | Nov 24 | Nov 25 | Nov 26 | Nov 27 | |
---|---|---|---|---|---|---|---|---|
Reported | - | - | - | $-93.26M | - | - | - | - |
Avg Forecast | $105.83M | $-55.33M | $-88.56M | $-101.35M | $-77.75M | $34.69M | $-89.58M | - |
High Forecast | $107.19M | $-44.26M | $-88.56M | $-81.08M | $-47.71M | $37.36M | $-88.11M | - |
Low Forecast | $104.02M | $-66.39M | $-88.56M | $-121.62M | $-119.61M | $32.01M | $-91.04M | - |
Surprise % | - | - | - | -7.98% | - | - | - | - |